Global Liquid Biopsy Market Worth USD 5,958.3 Milion by 2030 - Analysis, Technologies & Forecasts Report 2016-2030 - Vendors: RainDance Technologies, Genomic Health, Natera - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Liquid Biopsy Market Size & Forecast By Application, By Sample Type, By Biomarker Type, By Technology And Trend Analysis from 2013 To 2030" report to their offering.

Global liquid biopsies market is anticipated to reach 5,958.3 million by 2030. As these less invasive biopsies are able to address a number of significant challenges associated with conventional biopsies such as, high level of invasiveness, incompleteness of cancer information that is acquired, associated post-biopsy serious medical complications, and subsequent cost inclusions. A growing need for more advanced, efficient and accurate method which provides a holistic view of the tumor and metastasis is the prime factor fueling rapid development of liquid biopsies.

The market has gained considerable traction in the past couple of years. A number of clinical research projects related to circulating tumor cells, and cell-free tumor DNA have been initiated in the latter half of the past decade. As a result, there are a number of ongoing clinical trials that are due to be completed between post 2017-18.

Companies Mentioned:

  • Adaptive Biotechnologies
  • Biocept
  • Guardant Health
  • NeoGenomics Laboratories
  • Personal Genome Diagnostics
  • Qiagen
  • RainDance Technologies
  • Trovagene
  • Cynvenio
  • Epic Sciences
  • Exosome
  • Foundation Medicine
  • Genomic Health
  • Illumina Inc.
  • Angle Plc
  • Boreal Genomics
  • CareDx
  • Chronix Biomedical
  • Cynvenio Biosystems Inc.
  • Epic Sciences
  • Foundation Medicine
  • Natera Inc.
  • Pathway Genomics
  • Roche (Ariosa)
  • Sequenom
  • Trovagene

Report Structure:

1. Methodology and Scope

2. Executive Summary

3. Market Snapshot

4. Market Variables, Trends & Scope

5. Market Categorization 1: Application Estimates & Trend Analysis

6. Market Categorization 2: Sample Type Estimates & Trend Analysis

7. Market Categorization 3: Biomarker Estimates & Trend Analysis

8. Market Categorization 4: Technology Estimates & Trend Analysis

9. Market Categorization 3: Regional Estimates & Trend Analysis

10. Competitive Landscape

For more information about this report visit http://www.researchandmarkets.com/research/z5rvh9/liquid_biopsy

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biomarkers

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biomarkers